Cytiva acquires Vanrx Pharmasystems, Canadian aseptic filling innovator

Rhea-AI Summary

Cytiva has acquired Vanrx Pharmasystems, a Canadian firm specializing in robotic aseptic filling machines, marking its first acquisition since becoming an operating company of Danaher in April 2020. This acquisition aligns with global trends towards smaller batch manufacturing and personalized therapies in the growing USD 300 billion biologics market. The addition enhances Cytiva's solutions from drug development to drug product, facilitating faster delivery of therapies to patients. Vanrx's expertise in aseptic filling complements Cytiva's existing manufacturing capabilities.

Positive

• Cytiva enhances its manufacturing capacity solutions with the acquisition of Vanrx, focusing on aseptic filling to facilitate personalized therapies.
• The deal enables Cytiva to provide comprehensive 'idea to injection' solutions, improving the speed of biomanufacturing.
• Cytiva's integration of Vanrx's technology is expected to strengthen its FlexFactory platforms and KUBio modular facilities.

Negative

• None.

- Cytiva will now provide "idea to injection" solutions to customers and the market

- Addition to portfolio supports global trends towards smaller manufacturing and the advent of personalized therapies

- First acquisition by company since becoming Cytiva in April 2020

AMERSHAM, United Kingdom, Feb. 1, 2021 /PRNewswire/ -- Cytiva has acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients. 

This is the first acquisition by Cytiva. Emmanuel Ligner, President and CEO, Cytiva, says: "Since becoming a Danaher operating company in April 2020, we have already begun fueling innovation and re-investing in the business for the benefit of our customers and their patients.  We are thrilled to welcome the Vanrx associates to our family and look forward to working together on delivering meaningful solutions for biomanufacturers."

The Vanrx portfolio complements Cytiva's manufacturing capacity solutions. Whereas great progress has until now focused on drug substances, this innovation is focused on drug product, which is a critical last step before distribution to patients.  Global trends toward smaller batches and personalized therapies are changing the growing USD 300 billion biologics market[1], and the complete bioprocessing workflow must include aseptic filling solutions.

Olivier Loeillot, Vice President and Head of BioProcess, Cytiva, says: "Cytiva becomes the first 'idea to injection' biotechnology company by bringing Vanrx into our already strong portfolio. From drug development, through drug substance and now into drug product, we can help biomanufacturers bring their therapies to patients faster. Vanrx will enhance Cytiva FlexFactory platforms and KUBio modular facilities, enabling us to accelerate biomanufacturing from start to finish."

Vanrx's flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators. These standardized, flexible systems provide a fast and certain path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals. The company counts leading biopharmaceutical companies as its customers.

Vanrx was founded in 2007 by Chris Procyshyn and Ross Gold and currently has over 120 associates, all of whom have been offered employment with Cytiva.

Chris Procyshyn, Vanrx co-founder and CEO, says: "We created Vanrx to enable every company to manufacture safe and cost-effective injectable therapies. Our own experience told us that new technologies are needed to support next-generation therapies and personalized medicine.

"Cytiva is a perfect home for what we have built. Thanks to their reach, we will be able to help our current and future customers change the lives of even more patients around the world."

Producers: Click here for B-roll  of aseptic filling solutions.
Click here for more information about Cytiva's enterprise solutions.

###

About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

__________

1 BioPlan and Associates 17th Annual Biopharmaceutical Manufacturing Capacity and Production (April 2020)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cytiva-acquires-vanrx-pharmasystems-canadian-aseptic-filling-innovator-301218409.html

SOURCE Cytiva

FAQ

What is the impact of Cytiva's acquisition of Vanrx on the stock symbol DHR?

Cytiva's acquisition of Vanrx positions it to better serve the growing biologics market, potentially leading to higher revenues for DHR as it enhances manufacturing capabilities.

When did Cytiva acquire Vanrx Pharmasystems?

Cytiva announced the acquisition of Vanrx Pharmasystems on February 1, 2021.

What are Vanrx's key products following the acquisition by Cytiva?

Vanrx's key products include the SA25 Aseptic Filling Workcell and the Microcell Vial Filler, which automate aseptic filling in biopharmaceutical manufacturing.

How does the acquisition of Vanrx align with global market trends?

The acquisition supports the shift towards smaller batch manufacturing and personalized medicine in the rapidly expanding biologics sector.